ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1218

Discovering the Potential Application of Digital Biomarkers for Inflammatory Arthritis Patients, a Design Thinking Approach; Preliminary Results of the Patients’ Perspective
Abstract Number: 0157

Discovering the Potential of Digital Biomarkers in the Work Process of the Rheumatology Healthcare Professionals, a Design Thinking Approach; Preliminary Results of the Healthcare Professionals Perspective
Abstract Number: 0045

Discovery and Characterization of a Selective, Orally Bioavailable PAD4 Inhibitor to Target NETs Driven Autoimmune and Inflammatory Diseases
Abstract Number: 0061

Discovery of a RIPK2 Scaffolding Inhibitor for the Treatment of Joint Autoimmune Diseases
Abstract Number: 2505

Discovery of First-in-Class IRAK4 Scaffolding Inhibitors for the Treatment of Inflammatory Disorders
Abstract Number: 1476

Discriminating Disease Flare from Infection in Febrile Patients with Systemic Lupus Erythematosus Admitted to a Safety-Net Hospital System: A Retrospective, Multicenter Study
Abstract Number: 0377

Disease Activity and New Medication Start at Two Consecutive Registry Visits for Patients with Juvenile Idiopathic Arthritis
Abstract Number: 2205

Disease Activity and Widespread Pain Are the 2 Key Drivers of Global Health in Axial Spondyloarthritis, with Similar Findings in Different Patient Populations: An Analysis of 4 Databases and 6064 Patients
Abstract Number: 0403

Disease Activity Is Associated with Frailty in Veterans with Rheumatoid Arthritis
Abstract Number: 0349

Disease Activity of Juvenil Idiopathic Arthritis in Transitional Care
Abstract Number: 2263

Disease Activity Progression in Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS)
Abstract Number: 1547

Disease Burden of Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Retrospective Analysis of US Health Insurance Claims Data
Abstract Number: 2179

Disease Burden of Patients with Primary Sjögren’s Disease: Results from a Multinational Real-World Survey
Abstract Number: 0381

Disease Burden, Patient Experiences, and Unmet Needs in Refractory Rheumatoid Arthritis: Insights from 20 Years of Real-World Data
Abstract Number: 0273

Disease Characteristics and Pancreatic Damage in IgG4-Related Disease with Pancreatic Involvement

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].